# Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial

> **NCT06764095** · PHASE4 · RECRUITING · sponsor: **Mayo Clinic** · enrollment: 75 (estimated)

## Conditions studied

- Locally Advanced Bladder Urothelial Carcinoma
- Locally Advanced Renal Pelvis and Ureter Urothelial Carcinoma
- Metastatic Bladder Urothelial Carcinoma
- Metastatic Renal Pelvis and Ureter Urothelial Carcinoma
- Stage III Bladder Cancer AJCC v8
- Stage IV Bladder Cancer AJCC v8
- Stage IV Renal Pelvis and Ureter Cancer AJCC v8

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Cystectomy
- **DRUG:** Enfortumab Vedotin
- **PROCEDURE:** Local Therapy
- **PROCEDURE:** Magnetic Resonance Imaging
- **BIOLOGICAL:** Pembrolizumab
- **PROCEDURE:** Positron Emission Tomography
- **OTHER:** Questionnaire Administration
- **PROCEDURE:** Ureterectomy

## Key facts

- **NCT ID:** NCT06764095
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-08
- **Primary completion:** 2034-12-31
- **Final completion:** 2034-12-31
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2026-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06764095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06764095, "Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06764095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*